Dalteparin
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dalteparin".

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Eisai. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism.

The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than coumadin in reducing the risk of recurrent embolic events.^[1]

References

1. ^ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587. 

This medical treatment article is a stub. You can help Wikipedia by expanding it.